



A randomized controlled trial comparing inSPOT and patient-delivered partner therapy to standard partner notification among MSM: The good, the bad, and the ugly

Roxanne P. Kerani^{1,2}, Mark Fleming¹, Bill DeYoung¹, Matthew R. Golden^{1,2}

¹Public Health – Seattle and King County, ²University of Washington

Results Summary

- Of eligible patients, 81% declined enrollment
- 80% of MSM in the two PDPT arms gave PDPT to ≥1 partner
- More partners were treated per case in the PDPT arms combined compared to SPM
- inSPOT was used very infrequently
- Highest rates of HIV and syphilis testing occurred in persons receiving standard partner services

Background

- Among heterosexuals, patient-delivered partner therapy (PDPT) increases partner treatment and decreases rates of index case reinfection
- No published randomized trials have specifically sought to evaluate different partner notification strategies in MSM
- The effectiveness of PDPT among MSM is unknown
- The effectiveness of inSPOT, a web-based partner notification tool, is also unknown

Research Questions

- Among MSM, do PDPT or inSPOT increase partner notification or treatment, compared to standard partner management?
- Do PDPT or inSPOT result in fewer partners being tested for HIV and/or syphilis, compared to SPM?

Methods

- Study design: randomized, controlled trial
- Study population: MSM reported with gonorrhea or chlamydial infection.
- Participants enrolled at time of contact for partner management services (in STD Clinic or by telephone)
- Four arms:
 1. Patient delivered partner therapy (PDPT) - 1 g azithromycin; 400 mg cefixime (if patient had GC), allergy warning, STD information, condoms, invitation to STD Clinic
 2. inSPOT – participants in-clinic offered use of a computer in the clinic and given a card with website URL. Participants enrolled via telephone given web URL.
 3. Combined PDPT/inSPOT
 4. Standard partner management (SPM)– offer of assistance notifying partners
- Outcomes based on participant report at interview 2 weeks following enrollment or based on DIS recorded outcomes for partners contacted directly by DIS

Results

Figure 1: Study Enrollment




Table 1: Study participants


Participant characteristic	N	%
Enrollment		
By telephone	2	3.8
In STD Clinic	51	96.2
STD		
GC	27	50.9
CT	25	47.2
Coinfected	1	1.9
Race		
White	40	75.5
Black	2	3.8
Other	10	20.1
Age (mean, std)	31.1	9.0

Table 2: DIS management of partners and use of PDPT and inSPOT

	Participants	Partners	Partners managed by study staff	Patients who gave PDPT to ≥1 partner	Partners treated via PDPT	Patients who used inSPOT	Partners notified via inSPOT
PDPT	13	44	3 (6.8%) *	11 (84.6%)	33 (75%)	0	0
inSPOT	10	30	3 (10.3%)	1 (10%)	3 (10%)	0	0
PDPT/inSPOT	17	70	10 (14.3%)	13 (76.5%)	42 (60%)	1 (5.9%)	1 (1.4%)
SPM	13	42	14 (33.3%)	1 (7.7%)	1 (2.4%)	1 (7.7%)	2 (4.8%)
Total	53	186	30	26	79	2	3

* p<0.05 when compared to standard arm

Figure 2: Partners notified, treated and tested for HIV or syphilis per case



Limitations

- We did not reach target enrollment
- Limited power to detect differences
- Limited generalizability

Conclusions

- Population-based randomized trials of different approaches to partner management in MSM may not be feasible using standard, IRB approved protocols
- PDPT is acceptable to MSM, and may increase partner treatment among MSM
- PDPT may decrease HIV and syphilis testing in MSM
- Few MSM appear to be interested in using inSPOT